These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25402286)

  • 41. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
    Gomes DM; Smotherman C; Birch A; Dupree L; Della Vecchia BJ; Kraemer DF; Jankowski CA
    Pharmacotherapy; 2014 Jul; 34(7):662-9. PubMed ID: 24753221
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk factors for acute kidney injury in patients treated with polymyxin B at a Tertiary Care Medical Center.
    Bahlis LF; Diogo LP; Lemons D; Klaus D
    J Bras Nefrol; 2015; 37(4):446-50. PubMed ID: 26648493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Late-Occurring Vancomycin-Associated Acute Kidney Injury in Children Receiving Prolonged Therapy.
    Knoderer CA; Gritzman AL; Nichols KR; Wilson AC
    Ann Pharmacother; 2015 Oct; 49(10):1113-9. PubMed ID: 26160972
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vancomycin-associated renal dysfunction: where are we now?
    Carreno JJ; Kenney RM; Lomaestro B
    Pharmacotherapy; 2014 Dec; 34(12):1259-68. PubMed ID: 25220436
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients.
    LeCleir LK; Pettit RS
    Pediatr Pulmonol; 2017 Aug; 52(8):1000-1005. PubMed ID: 28440913
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function.
    Jeon N; Staley B; Klinker KP; Hincapie Castillo J; Winterstein AG
    Int J Antimicrob Agents; 2017 Jul; 50(1):63-67. PubMed ID: 28522340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vancomycin nephrotoxicity may be overstated.
    Moffett BS; Kim S; Edwards M
    J Pediatr; 2011 May; 158(5):865-6; author reply 866. PubMed ID: 21324473
    [No Abstract]   [Full Text] [Related]  

  • 48. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute Kidney Injury Associated With Vancomycin When Laxity Leads to Injury and Findings on Kidney Biopsy.
    Katikaneni M; Lwin L; Villanueva H; Yoo J
    Am J Ther; 2016; 23(4):e1064-7. PubMed ID: 26035034
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vancomycin nephrotoxicity: myths and facts.
    Gupta A; Biyani M; Khaira A
    Neth J Med; 2011 Sep; 69(9):379-83. PubMed ID: 21978980
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vancomycin nephrotoxicity: a review.
    Mergenhagen KA; Borton AR
    J Pharm Pract; 2014 Dec; 27(6):545-53. PubMed ID: 25266809
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vancomycin Should Be Considered a Nephrotoxic Antimicrobial Agent: PRO.
    Murphy ME; Barreto EF
    Kidney360; 2022 Sep; 3(9):1484-1487. PubMed ID: 36245668
    [No Abstract]   [Full Text] [Related]  

  • 53. Evaluation of body weight-based vancomycin therapy and the incidence of nephrotoxicity: a retrospective study in the northwest of China.
    Dong MH; Wang JW; Wu Y; Chen BY; Yu M; Wen AD
    Int J Infect Dis; 2015 Aug; 37():125-8. PubMed ID: 26159843
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute renal failure after topical fortified gentamicin and vancomycin eyedrops.
    Tang RK; Tse RK
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):411-3. PubMed ID: 21702685
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vancomycin-Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention.
    Pais GM; Liu J; Zepcan S; Avedissian SN; Rhodes NJ; Downes KJ; Moorthy GS; Scheetz MH
    Pharmacotherapy; 2020 May; 40(5):438-454. PubMed ID: 32239518
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk of vancomycin-induced nephrotoxicity in the population with chronic kidney disease.
    Panwar B; Johnson VA; Patel M; Balkovetz DF
    Am J Med Sci; 2013 May; 345(5):396-9. PubMed ID: 23103440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New target concentrations for vancomycin in Hong Kong.
    You JH; Chow SS; Lui JW; Ip M
    Int J Antimicrob Agents; 2011 Jan; 37(1):83-4. PubMed ID: 21074378
    [No Abstract]   [Full Text] [Related]  

  • 58. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship.
    Karino S; Kaye KS; Navalkele B; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Pogue JM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3743-50. PubMed ID: 27067325
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury.
    O'Donnell JN; Rhodes NJ; Lodise TP; Prozialeck WC; Miglis CM; Joshi MD; Venkatesan N; Pais G; Cluff C; Lamar PC; Briyal S; Day JZ; Gulati A; Scheetz MH
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807910
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is the Combination of Piperacillin-Tazobactam and Vancomycin Associated with Development of Acute Kidney Injury? A Meta-analysis.
    Giuliano CA; Patel CR; Kale-Pradhan PB
    Pharmacotherapy; 2016 Dec; 36(12):1217-1228. PubMed ID: 27805728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.